Millions of books in English, Spanish and other languages. Free UK delivery 

menu

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo
Type
Physical Book
Publisher
Language
English
Pages
114
Format
Paperback
Dimensions
23.4 x 15.6 x 0.6 cm
Weight
0.17 kg.
ISBN13
9781680838206

Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo

John T. Scott (Author) · Robert S. Danziger (Author) · Now Publishers · Paperback

Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo - Danziger, Robert S. ; Scott, John T.

Physical Book

£ 76.96

  • Condition: New
Origin: U.S.A. (Import costs included in the price)
It will be shipped from our warehouse between Thursday, June 20 and Monday, July 08.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.

Synopsis "Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo"

This study develops a detailed description of the successful technology transfer of an invention - the drug-eluting coronary stent - originating in intramural research within the US National Institutes of Health. The history of the commercialization of the invention is used to illustrate a new policy, proposed and explained in this study, for the payment to the government of royalties on the sales of biomedical products developed with substantial public funding provided through indirect as well as direct funding avenues. The proposed policy addresses concerns about the high prices that taxpayers as consumers pay for biomedical products that were developed with funding from the taxpayers as investors. The study explains the theoretical circumstances in which the policy would not adversely affect the appropriate level of R&D investment, and then uses the history of the drug-eluting coronary stent as an example where biomedical R&D is consistent with those circumstances.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews